Search research articles
Contact Us
Filters
Showing results (51-60 of 464) with videos related to
Page
of 47
Sort By:
Clinical Pharmacology and Therapeutics
|
February 24, 2012
Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms
Ingrid Ordás, Diane R Mould, Brian G Feagan, et al.
The American Journal of Gastroenterology
|
May 28, 2009
Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease
Brian G Feagan, Geoffroy Coteur, Seng Tan, et al.
The American Journal of Gastroenterology
|
October 24, 2003
The effects of infliximab maintenance therapy on health-related quality of life
Brian G Feagan, Songkai Yan, Mohan Bala, et al.
Gastroenterology
|
November 5, 2003
AGA technical review on perianal Crohn's disease
William J Sandborn, Victor W Fazio, Brian G Feagan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 8, 2020
Managing Inflammatory Bowel Disease During COVID-19: Summary of Recommendations from Gastrointestinal Societies
Jurij Hanzel, Christopher Ma, John K Marshall, et al.
Expert Opinion on Biological Therapy
|
July 9, 2024
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease
Gary R Lichtenstein, Arif Soonasra, Mark Latymer, et al.
Gastroenterology & Hepatology
|
February 26, 2024
Case Report: Medical Management of Acute Severe Ulcerative Colitis
Sudheer Kumar Vuyyuru, Vipul Jairath, Jurij Hanžel, et al.
Inflammatory Bowel Diseases
|
December 6, 2014
Clinical remission as defined by the Mayo Score: do we deceive ourselves?
Mark A Samaan, Brian G Feagan, Willam J Sandborn, et al.
Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association
|
August 1, 2015
A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease
Mahmoud H Mosli, Othman Al-Harbi, Brian G Feagan, et al.
The American Journal of Gastroenterology
|
November 29, 2007
Health-related quality of life during natalizumab maintenance therapy for Crohn's disease
Brian G Feagan, William J Sandborn, Steven Hass, et al.
Page
of 47
Search research articles
Search
Showing results (51-60 of 464) with videos related to
Sort By:
Page
of 47
Clinical Pharmacology and Therapeutics
|
February 24, 2012
Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms
Ingrid Ordás, Diane R Mould, Brian G Feagan, et al.
The American Journal of Gastroenterology
|
May 28, 2009
Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease
Brian G Feagan, Geoffroy Coteur, Seng Tan, et al.
The American Journal of Gastroenterology
|
October 24, 2003
The effects of infliximab maintenance therapy on health-related quality of life
Brian G Feagan, Songkai Yan, Mohan Bala, et al.
Gastroenterology
|
November 5, 2003
AGA technical review on perianal Crohn's disease
William J Sandborn, Victor W Fazio, Brian G Feagan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 8, 2020
Managing Inflammatory Bowel Disease During COVID-19: Summary of Recommendations from Gastrointestinal Societies
Jurij Hanzel, Christopher Ma, John K Marshall, et al.
Expert Opinion on Biological Therapy
|
July 9, 2024
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease
Gary R Lichtenstein, Arif Soonasra, Mark Latymer, et al.
Gastroenterology & Hepatology
|
February 26, 2024
Case Report: Medical Management of Acute Severe Ulcerative Colitis
Sudheer Kumar Vuyyuru, Vipul Jairath, Jurij Hanžel, et al.
Inflammatory Bowel Diseases
|
December 6, 2014
Clinical remission as defined by the Mayo Score: do we deceive ourselves?
Mark A Samaan, Brian G Feagan, Willam J Sandborn, et al.
Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association
|
August 1, 2015
A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease
Mahmoud H Mosli, Othman Al-Harbi, Brian G Feagan, et al.
The American Journal of Gastroenterology
|
November 29, 2007
Health-related quality of life during natalizumab maintenance therapy for Crohn's disease
Brian G Feagan, William J Sandborn, Steven Hass, et al.
Page
of 47